amantadine has been researched along with Dyskinesia, Drug-Induced in 118 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need." | 9.24 | ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. ( Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD, 2017) |
| "The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID)." | 9.19 | Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. ( Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M, 2014) |
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 9.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "Medical treatment of levodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need." | 5.24 | ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. ( Agarwal, P; Hauser, RA; Hull, KL; Isaacson, SH; Johnson, R; Lyons, KE; Nausieda, PA; Pahwa, R; Stempien, MJ; Tanner, CM; Truong, DD, 2017) |
| "The AMANDYSK trial was designed to assess long-term efficacy of chronic treatment with amantadine in patients with Parkinson disease (PD) and levodopa-induced dyskinesia (LID)." | 5.19 | Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. ( Azulay, JP; Bonnet, AM; Brefel-Courbon, C; Corvol, JC; Damier, P; Dellapina, E; Destée, A; Durif, F; Galitzky, M; Lebouvier, T; Meissner, W; Ory-Magne, F; Rascol, O; Salis, A; Sommet, A; Thalamas, C; Tison, F; Viallet, F; Vidailhet, M, 2014) |
| "Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0." | 5.10 | Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. ( Chase, TN; Farmer, C; Gillespie, M; Morris, MJ; Mosby, K; Verhagen Metman, L; Wuu, J, 2002) |
| " In more than 50 percent of the cases of initial tremor induced by lithium therapy, oxprenolol in daily doses of 160--240 mg produced good effects and moderate improvement was noted in a few further cases." | 5.04 | Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. ( Pöldinger, W, 1978) |
| "After chronic levodopa use, many patients with Parkinson disease (PD) develop involuntary movements." | 3.80 | Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism? ( Lewitt, PA; Mouradian, MM, 2014) |
| "The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy." | 2.84 | Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). ( Azulay, JP; Eggert, K; Ehret, R; Felt, L; Hauser, RA; Isaacson, S; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM; Trenkwalder, C, 2017) |
| "Lay abstract Parkinson's disease (PD) is a common neurodegenerative disease." | 2.82 | GOCOVRI ( Müller, T, 2022) |
| "Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability." | 2.78 | Which dyskinesia scale best detects treatment response? ( Chung, KA; Ge, S; Goetz, CG; Hauser, RA; Jaglin, JA; Miyasaki, JM; Nicholas, AP; Nutt, JG; Poewe, W; Rascol, O; Seppi, K; Stacy, MA; Stebbins, GT; Tanner, CM; Urkowitz, A, 2013) |
| "Aripiprazole is a novel antipsychotic medication characterized by partial agonism at the D2 and 5-HT1A receptors and by antagonism at the 5-HT2A receptor." | 2.74 | Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study. ( Bernardi, S; Edito, F; Meco, G; Purcaro, C; Stirpe, P; Valente, M; Vanacore, N, 2009) |
| "Amantadine was first reported effective in the treatment of Parkinson's disease in 1969 and several studies were published in the 1970s supporting its efficacy." | 2.72 | Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease? ( Feldman, M; Margolesky, J; Marmol, S; Singer, C, 2021) |
| " Twenty-four drug-related adverse events were recorded of which four were regarded as serious." | 2.72 | Efficacy and safety of high-dose cabergoline in Parkinson's disease. ( Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G, 2006) |
| "UPDRS (Unified Parkinson's disease rating scale), dyskinesias rating scale (DRS) and IGA (investigator global assessment) scale were used to evaluate the severity of PD symptoms during follow-up." | 2.70 | Amantadine for dyskinesia in patients affected by severe Parkinson's disease. ( Onofrj, M; Paci, C; Thomas, A, 2001) |
| "or biperiden 2 mg b." | 2.68 | No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. ( Geraisy, N; Schwartz, M; Silver, H, 1995) |
| "Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD)." | 2.61 | Extended-Release Amantadine for Levodopa-Induced Dyskinesia. ( Dashtipour, K; Lyons, KE; Pahwa, R; Tafreshi, AR, 2019) |
| " The most common adverse reactions with amantadine are constipation, cardiovascular dysfunction including QT prolongation, orthostatic hypotension and edema, neuropsychiatric symptoms such as hallucinations, confusion and delirium, nausea and livedo reticularis." | 2.58 | Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. ( Perez-Lloret, S; Rascol, O, 2018) |
| " While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require deep brain stimulation to control their troublesome motor fluctuations and LIDs." | 2.53 | Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. ( Jankovic, J; Vijayakumar, D, 2016) |
| " Wearing-off can be treated by dietary manipulation, shortening the dosing interval, substituting sustained-release levodopa, adding amantadine, or monoamine oxidase type B inhibitors, and other options, including catechol-O-methyltransferase inhibitors and the approved dopamine agonists addressed in another chapter." | 2.43 | Other pharmacological treatments for motor complications and dyskinesias. ( Waters, C, 2005) |
| "Amantadine use was associated with delayed LID onset in the 6- and 12-month landmark analyses, with adjusted hazard ratios of 0." | 1.72 | Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease. ( Lin, CH; Lin, FJ; Tai, CH; Wang, CC; Wu, RM; Wu, TL, 2022) |
| "Amantadine (10 mg/kg PO) was tested as a positive control." | 1.56 | The selective 5-HT ( Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A, 2020) |
| " Amantadine ER provides higher and more continuous amantadine plasma bioavailability than conventional immediate-release formulations, which require administration up to three times daily." | 1.51 | Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. ( Möhr, JD; Müller, T, 2019) |
| "Metformin is a medication that is widely prescribed for the management of type 2 diabetes." | 1.48 | Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease. ( Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Lee, TG; Noh, JR; Park, HY; Ryu, YK, 2018) |
| " The primary outcome measure was safety assessed through adverse events (AEs)." | 1.46 | ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. ( Felt, L; Hauser, RA; Isaacson, SH; Johnson, R; Oertel, W; Pahwa, R; Stempien, MJ; Tanner, CM, 2017) |
| " This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM." | 1.40 | Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat ( Balan, G; Barreiro, G; Boscoe, BP; Chen, L; Chenard, LK; Cianfrogna, J; Claffey, MM; Coffman, KJ; Drozda, SE; Dunetz, JR; Fonseca, KR; Galatsis, P; Grimwood, S; Lazzaro, JT; Mancuso, JY; Miller, EL; Reese, MR; Rogers, BN; Sakurada, I; Shaffer, CL; Skaddan, M; Smith, DL; Stepan, AF; Trapa, P; Tuttle, JB; Verhoest, PR; Walker, DP; Wright, AS; Zaleska, MM; Zasadny, K; Zhang, L, 2014) |
| "Levodopa is the most effective medical treatment for Parkinson disease." | 1.38 | Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. ( Tarsy, D, 2012) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Our results demonstrate that chronic administration of a low-dose levodopa preparation can provide satisfactory benefit with a low incidence of motor complications, and can result in good QOL in Japanese patients with PD." | 1.33 | Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study. ( Kitagawa, M; Tashiro, K, 2005) |
| "Treatment with amantadine should routinely be considered before indicating pallidotomy for levodopa-induced dyskinesias." | 1.31 | [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease]. ( Cersósimo, MG; Micheli, FE; Scorticati, MC, 2000) |
| " In the statistical investigation by the multivariate analysis (quantification method type II), the age of initial levodopa therapy, the duration from the onset to the initiation of levodopa therapy, and the duration of levodopa therapy were not closely related to the development of any adverse reaction, while Hoehn & Yahr's stage and the dosage of levodopa had the most significant influence on the development of adverse reactions." | 1.30 | [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease]. ( Endo, S; Hikiji, A; Nakamura, Y; Yoshinaga, J, 1997) |
| "The drug treatment of Parkinson's disease should be tailored to the age of the patient, coexistence of dementia or postural hypotension, duration of the disease process and the emergence of side effects." | 1.27 | The drug treatment of Parkinson's disease. ( Morris, JG, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (18.64) | 18.7374 |
| 1990's | 14 (11.86) | 18.2507 |
| 2000's | 20 (16.95) | 29.6817 |
| 2010's | 43 (36.44) | 24.3611 |
| 2020's | 19 (16.10) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Balan, G | 1 |
| Barreiro, G | 1 |
| Boscoe, BP | 1 |
| Chenard, LK | 1 |
| Cianfrogna, J | 1 |
| Claffey, MM | 1 |
| Chen, L | 1 |
| Coffman, KJ | 1 |
| Drozda, SE | 1 |
| Dunetz, JR | 1 |
| Fonseca, KR | 1 |
| Galatsis, P | 1 |
| Grimwood, S | 1 |
| Lazzaro, JT | 1 |
| Mancuso, JY | 1 |
| Miller, EL | 1 |
| Reese, MR | 1 |
| Rogers, BN | 1 |
| Sakurada, I | 1 |
| Skaddan, M | 1 |
| Smith, DL | 1 |
| Stepan, AF | 1 |
| Trapa, P | 1 |
| Tuttle, JB | 1 |
| Verhoest, PR | 1 |
| Walker, DP | 1 |
| Wright, AS | 1 |
| Zaleska, MM | 1 |
| Zasadny, K | 1 |
| Shaffer, CL | 1 |
| Marmol, S | 1 |
| Feldman, M | 1 |
| Singer, C | 2 |
| Margolesky, J | 1 |
| Rascol, O | 7 |
| Fabbri, M | 1 |
| Poewe, W | 4 |
| Müller, T | 3 |
| Wang, CC | 1 |
| Wu, TL | 1 |
| Lin, FJ | 1 |
| Tai, CH | 1 |
| Lin, CH | 1 |
| Wu, RM | 1 |
| Tönges, L | 1 |
| deVries, T | 1 |
| Jaros, M | 1 |
| Quartel, A | 1 |
| Jacobs, D | 1 |
| Calderón, VM | 1 |
| Luna-Leal, A | 1 |
| Gómez-Paz, A | 1 |
| Ramírez-López, F | 1 |
| Arias-García, M | 1 |
| Lara-González, E | 1 |
| Galarraga, E | 1 |
| Bargas, J | 1 |
| Cohen, SR | 1 |
| Terry, ML | 1 |
| Coyle, M | 1 |
| Wheelis, E | 1 |
| Centner, A | 1 |
| Smith, S | 1 |
| Glinski, J | 1 |
| Lipari, N | 1 |
| Budrow, C | 1 |
| Manfredsson, FP | 1 |
| Bishop, C | 1 |
| Takeda, A | 1 |
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 3 |
| Murakami, Y | 1 |
| Nishijima, H | 1 |
| Nakamura, T | 1 |
| Furukawa, T | 1 |
| Kinoshita, I | 1 |
| Kon, T | 1 |
| Suzuki, C | 1 |
| Tomiyama, M | 1 |
| Pogorelov, VM | 1 |
| Martini, ML | 1 |
| Jin, J | 1 |
| Wetsel, WC | 1 |
| Caron, MG | 1 |
| Pajo, AT | 1 |
| Espiritu, AI | 1 |
| Jamora, RDG | 1 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Egan, T | 1 |
| Clark, I | 1 |
| Vissel, B | 1 |
| Tanner, CM | 6 |
| Pahwa, R | 7 |
| Hauser, RA | 8 |
| Oertel, WH | 2 |
| Isaacson, SH | 3 |
| Jankovic, J | 2 |
| Johnson, R | 5 |
| Chernick, D | 1 |
| Hubble, J | 1 |
| Zheng, C | 1 |
| Xu, Y | 1 |
| Chen, G | 1 |
| Tan, Y | 1 |
| Zeng, W | 1 |
| Wang, J | 1 |
| Cheng, C | 1 |
| Yang, X | 1 |
| Nie, S | 1 |
| Zhang, Z | 1 |
| Cao, X | 1 |
| Arakawa, K | 1 |
| Yuge, N | 1 |
| Maehara, S | 1 |
| Shen, W | 1 |
| Ren, W | 1 |
| Zhai, S | 1 |
| Yang, B | 1 |
| Vanoye, CG | 1 |
| Mitra, A | 1 |
| George, AL | 1 |
| Surmeier, DJ | 1 |
| AlShimemeri, S | 1 |
| Fox, SH | 5 |
| Visanji, NP | 2 |
| Depoortere, R | 1 |
| Johnston, TH | 4 |
| Brotchie, JM | 4 |
| Newman-Tancredi, A | 1 |
| Nausieda, PA | 1 |
| Truong, DD | 2 |
| Agarwal, P | 1 |
| Hull, KL | 1 |
| Lyons, KE | 2 |
| Stempien, MJ | 4 |
| Goetz, CG | 2 |
| Stebbins, GT | 2 |
| Chung, KA | 2 |
| Nicholas, AP | 2 |
| Merkitch, D | 1 |
| Stacy, MA | 2 |
| Oertel, W | 2 |
| Felt, L | 3 |
| Eggert, K | 1 |
| Trenkwalder, C | 1 |
| Ehret, R | 1 |
| Azulay, JP | 2 |
| Isaacson, S | 2 |
| Ryu, YK | 1 |
| Park, HY | 1 |
| Go, J | 1 |
| Choi, DH | 1 |
| Kim, YH | 1 |
| Hwang, JH | 1 |
| Noh, JR | 1 |
| Lee, TG | 1 |
| Lee, CH | 1 |
| Kim, KS | 1 |
| Loiodice, S | 1 |
| Denibaud, AS | 1 |
| Deffains, W | 1 |
| Alix, M | 1 |
| Montagne, P | 1 |
| Seffals, M | 1 |
| Drieu La Rochelle, C | 1 |
| He, ZF | 1 |
| Chen, J | 1 |
| Zhou, CN | 1 |
| Rao, Z | 1 |
| Wang, XH | 1 |
| Perez-Lloret, S | 1 |
| Elmer, LW | 2 |
| Juncos, JL | 1 |
| Criswell, SR | 1 |
| Parashos, S | 1 |
| Patni, R | 2 |
| Elkurd, MT | 1 |
| Bahroo, LB | 1 |
| Paik, J | 1 |
| Keam, SJ | 1 |
| Dashtipour, K | 1 |
| Tafreshi, AR | 1 |
| Kuhn, W | 1 |
| Möhr, JD | 2 |
| Kremens, DE | 1 |
| Kreitzman, DL | 1 |
| Walsh, RR | 1 |
| Howard, R | 1 |
| Nguyen, JT | 1 |
| Huot, P | 1 |
| Koprich, JB | 1 |
| Szeliga, KT | 1 |
| James, JW | 1 |
| Graef, JD | 1 |
| Letchworth, SR | 1 |
| Jordan, KG | 1 |
| Hill, MP | 2 |
| Ory-Magne, F | 2 |
| Corvol, JC | 1 |
| Bonnet, AM | 1 |
| Brefel-Courbon, C | 1 |
| Damier, P | 1 |
| Dellapina, E | 1 |
| Destée, A | 1 |
| Durif, F | 1 |
| Galitzky, M | 1 |
| Lebouvier, T | 1 |
| Meissner, W | 1 |
| Thalamas, C | 1 |
| Tison, F | 1 |
| Salis, A | 1 |
| Sommet, A | 1 |
| Viallet, F | 1 |
| Vidailhet, M | 1 |
| Rodnitzky, RL | 1 |
| Narayanan, NS | 1 |
| Ko, WK | 1 |
| Pioli, E | 1 |
| Li, Q | 2 |
| McGuire, S | 1 |
| Dufour, A | 1 |
| Sherer, TB | 1 |
| Bezard, E | 3 |
| Facheris, MF | 1 |
| Lewitt, PA | 1 |
| Mouradian, MM | 2 |
| Friedman, JH | 1 |
| Sethi, K | 1 |
| Truong, D | 1 |
| Struck, L | 1 |
| Ruby, AE | 1 |
| McClure, NL | 1 |
| Went, GT | 1 |
| Mazzucchi, S | 1 |
| Frosini, D | 1 |
| Bonuccelli, U | 3 |
| Ceravolo, R | 1 |
| Bortolanza, M | 1 |
| Bariotto-Dos-Santos, KD | 1 |
| Dos-Santos-Pereira, M | 1 |
| da-Silva, CA | 1 |
| Del-Bel, E | 1 |
| Vijayakumar, D | 1 |
| Thomsen, BL | 1 |
| Herz, DM | 1 |
| Siebner, HR | 1 |
| Løkkegaard, A | 1 |
| Meco, G | 1 |
| Stirpe, P | 1 |
| Edito, F | 1 |
| Purcaro, C | 1 |
| Valente, M | 1 |
| Bernardi, S | 1 |
| Vanacore, N | 1 |
| Wolf, E | 1 |
| Seppi, K | 2 |
| Katzenschlager, R | 1 |
| Hochschorner, G | 1 |
| Ransmayr, G | 1 |
| Schwingenschuh, P | 1 |
| Ott, E | 1 |
| Kloiber, I | 1 |
| Haubenberger, D | 1 |
| Auff, E | 1 |
| Spinnewyn, B | 1 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 1 |
| Auguet, M | 1 |
| Howland, RH | 1 |
| Bido, S | 1 |
| Marti, M | 1 |
| Morari, M | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Nepoklonov, AV | 1 |
| Kokshenev, II | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Fisone, G | 2 |
| Kobylecki, C | 1 |
| Crossman, AR | 1 |
| Ravenscroft, P | 1 |
| Sander, SE | 1 |
| Lemm, C | 1 |
| Lange, N | 1 |
| Hamann, M | 1 |
| Richter, A | 1 |
| Tarsy, D | 1 |
| Elahi, B | 1 |
| Phielipp, N | 1 |
| Chen, R | 1 |
| Breger, LS | 1 |
| Dunnett, SB | 1 |
| Lane, EL | 1 |
| Tronci, E | 1 |
| Pioli, EY | 1 |
| Porras, G | 1 |
| Björklund, A | 1 |
| Carta, M | 2 |
| Miyasaki, JM | 1 |
| Nutt, JG | 1 |
| Urkowitz, A | 1 |
| Jaglin, JA | 1 |
| Ge, S | 1 |
| Verhagen Metman, L | 2 |
| Morris, MJ | 1 |
| Farmer, C | 1 |
| Gillespie, M | 1 |
| Mosby, K | 1 |
| Wuu, J | 1 |
| Chase, TN | 6 |
| Blanchet, PJ | 2 |
| Metman, LV | 3 |
| Lucetti, C | 1 |
| Gambaccini, G | 2 |
| Bernardini, S | 2 |
| Dell'Agnello, G | 1 |
| Petrozzi, L | 1 |
| Rossi, G | 1 |
| Furukawa, Y | 1 |
| Filiano, JJ | 1 |
| Kish, SJ | 1 |
| Lee, J | 1 |
| Gomez-Ramirez, J | 2 |
| Kurlan, R | 1 |
| Waters, C | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Cenci, MA | 1 |
| da Silva-Júnior, FP | 1 |
| Braga-Neto, P | 1 |
| Sueli Monte, F | 1 |
| de Bruin, VM | 1 |
| Kitagawa, M | 1 |
| Tashiro, K | 1 |
| Odin, P | 1 |
| Oehlwein, C | 1 |
| Storch, A | 1 |
| Polzer, U | 1 |
| Werner, G | 1 |
| Renner, R | 1 |
| Shing, M | 1 |
| Ludolph, A | 1 |
| Schüler, P | 1 |
| Konitsiotis, S | 3 |
| Tsironis, C | 1 |
| Kiortsis, DN | 1 |
| Evangelou, A | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Borison, RL | 3 |
| Diamond, BI | 1 |
| Weiner, M | 1 |
| Alphs, L | 1 |
| Davis, JM | 2 |
| Tegeler, J | 1 |
| Wöller, W | 1 |
| Allen, RM | 1 |
| Wesemann, W | 1 |
| Sontag, KH | 1 |
| Maj, J | 1 |
| Morris, JG | 2 |
| Parkes, JD | 1 |
| Calne, DB | 1 |
| Silver, H | 1 |
| Geraisy, N | 1 |
| Schwartz, M | 1 |
| Freudenreich, O | 1 |
| McEvoy, JP | 2 |
| Mizuno, T | 1 |
| Kurisaki, H | 1 |
| Yamada, K | 1 |
| Kanba, S | 1 |
| Ohnishi, K | 1 |
| Ashikari, I | 1 |
| Yagi, G | 1 |
| Asai, M | 1 |
| Nakamura, Y | 1 |
| Yoshinaga, J | 1 |
| Endo, S | 1 |
| Hikiji, A | 1 |
| Quinn, NP | 1 |
| Del Dotto, P | 3 |
| van den Munckhof, P | 1 |
| Fang, J | 2 |
| Rajput, AH | 1 |
| Rajput, A | 1 |
| Lang, AE | 1 |
| Kumar, R | 1 |
| Uitti, RJ | 1 |
| Galvez-Jimenez, N | 1 |
| Sunohara, N | 1 |
| Vale, S | 1 |
| LePoole, K | 1 |
| Ahlskog, JE | 1 |
| Angus, S | 1 |
| Sugars, J | 1 |
| Boltezar, R | 1 |
| Koskewich, S | 1 |
| Schneider, NM | 1 |
| Luginger, E | 1 |
| Wenning, GK | 1 |
| Bösch, S | 1 |
| Cersósimo, MG | 1 |
| Scorticati, MC | 1 |
| Micheli, FE | 1 |
| Pavese, N | 1 |
| Paci, C | 1 |
| Thomas, A | 1 |
| Onofrj, M | 1 |
| Carroll, BJ | 1 |
| Curtis, GC | 1 |
| Kokmen, E | 1 |
| Pöldinger, W | 1 |
| González, ER | 1 |
| Jeste, DV | 1 |
| Wyatt, RJ | 1 |
| Schneider, E | 1 |
| Fischer, PA | 1 |
| Jacobi, P | 1 |
| Ankenman, R | 1 |
| Greer, M | 1 |
| McCue, M | 1 |
| Freter, S | 1 |
| Lieberman, AN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)[NCT02136914] | Phase 3 | 126 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)[NCT02202551] | Phase 3 | 223 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)[NCT02274766] | Phase 3 | 77 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)[NCT00127114] | Phase 4 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to No funding and exclusion criteria were to stringent.) | ||
| Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease[NCT00794313] | 3 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to Funding Ended) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -8.0 |
| ADS-5102 (340 mg) | -15.9 |
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 24
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| ADS-5102 (340 mg) | -15.6 |
The MDS-UPDRS Parts I, II, and III examined non-motor experiences of daily living, motor experiences of daily living, and motor examination, respectively. Each Part contains items or questions that were each rated on a scale from 0 (normal) to 4 (severe). The Combined Parts I, II, and III (representing the sum of the individual scores from Parts I, II, and III) has a scale range of 0-236. Higher scores, whether for individual Parts or the sum of the combined Parts, indicate more severe PD. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| Change from BL at Week 12 | Change from BL at Week 24 | |
| ADS-5102 (340 mg) | -5.2 | -1.3 |
| Placebo | -4.0 | -3.5 |
A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 8, 12, 18, and 24 visits. (NCT02136914)
Timeframe: Baseline (BL) to Week 12 (W12) and Week 24 (W24)
| Intervention | hours (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Change in ON time w/o troublesome dyskinesia (W12) | Change in ON time w/o troublesome dyskinesia (W24) | Change in OFF time (W12) | Change in OFF time (W24) | Change in ON time w/ troublesome dyskinesia (W12) | Change in ON time w/ troublesome dyskinesia (W24) | |
| ADS-5102 (340 mg) | 3.56 | 3.59 | -0.59 | -0.58 | -3.12 | -3.31 |
| Placebo | 0.82 | 1.37 | 0.32 | 0.22 | -1.58 | -1.86 |
The CGI-C consisted of a single question that assessed the investigator's global impression of the subject's change from Baseline in overall PD symptoms, including but not limited to LID. The CGI-C required that the investigator rate the extent to which the subject's PD had improved or worsened (from marked worsening to marked improvement). The CGI-C was assessed at Baseline and Weeks 2, 8, 12, 18, and 24. (NCT02136914)
Timeframe: Baseline to Week 12 and Week 24
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1271965983 | Week 1271965984 | Week 2471965984 | Week 2471965983 | |||||||||||||||||||||||||
| Moderate Improvement | Minimal Improvement | No Change | Minimal Worsening | Moderate Worsening | Marked Worsening | Marked Improvement | ||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 18 | |||||||||||||||||||||||||||
| Placebo | 9 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 20 | |||||||||||||||||||||||||||
| Placebo | 10 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 13 | |||||||||||||||||||||||||||
| Placebo | 25 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 9 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 2 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 0 | |||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 1 | |||||||||||||||||||||||||||
| Placebo | 5 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 14 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 17 | |||||||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 12 | |||||||||||||||||||||||||||
| Placebo | 17 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 7 | |||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||
| ADS-5102 (340 mg) | 5 | |||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||
"To evaluate clinical progression of PD as assessed by the MDS-UPDRS, combined score, Parts I, II, and III.~Part I - non-motor experiences of daily living; Part II - motor experiences of daily living; Part III - motor examination. Parts I and II each contain 13 questions measured on a 5-point scale (0-4). Part III contains 18 objective rater assessments of the motor signs of PD measured on a 5-point scale (0-4).~Total range for combined score (Part I-III) is = 0-176. Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better.~Parts I, II, and III are summed to make the total score." (NCT02202551)
Timeframe: Up to 101 weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from Baseline at Week 8 | Change from Baseline at Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| ADS-5102 1A | 41.8 | 1.2 | 1.6 | 4.8 | 7.5 | 13.2 | 8.8 | 11.7 | 11.3 | 11.4 |
| ADS-5102 Group 1P | 45.6 | -2.8 | -1.4 | 1.5 | -0.4 | 2.6 | 2.6 | 7.3 | 3.7 | 3.7 |
| ADS-5102 Group 2 | 52.8 | 0.8 | 5.7 | 6.5 | 1.6 | 6.1 | 6.1 | 9.4 | 6.4 | 6.5 |
| ADS-5102 Group 3 | 52.4 | -5.3 | -5.2 | -5.3 | -4.8 | -4.6 | -4.6 | -4.9 | 0.9 | 4.1 |
"This component (Questions 4.1 - 4.6) includes time spent with dyskinesia, functional impact of dyskinesia, time spent in OFF state, functional impact of fluctuations, complexity of motor fluctuations, painful OFF-state dystonia. Questions 4.1-4.6 are summed to make the Part IV score.~Generally for MDS-UPDRS scores and sub-scores, the lower the score, the better. Total range for Part IV is = 0-24" (NCT02202551)
Timeframe: 100 Weeks. MDS-UPDRS was performed at the following visits: Screening, Week 8, Week 16, Week 28, Week 40, Week 52, Week 64, Week 76, Week 88, Week 100 (or ET).
| Intervention | units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change in Baseline from Week 8 | Change in Baseline from Week 16 | Change from Baseline at Week 28 | Change from Baseline at Week 40 | Change from Baseline at Week 52 | Change from Baseline at Week 64 | Change from Baseline at Week 76 | Change from Baseline at Week 88 | Change from Baseline at Week 100 | |
| Group 1a | 6.5 | -0.2 | -0.8 | -0.3 | 0.0 | 0.2 | 0.4 | 0.9 | 0.4 | 0.4 |
| Group 1P | 9.6 | -3.4 | -3.2 | -3.3 | -2.8 | -2.9 | -3.3 | -2.9 | -2.8 | -2.4 |
| Group 2 | 9.8 | -3.6 | -1.1 | -1.4 | -2.9 | -2.5 | -1.9 | -2.7 | -3.7 | -3.6 |
| Group 3 | 10.4 | -4.0 | -3.9 | -4.4 | -4.7 | -3.6 | -2.5 | -3.7 | -4.3 | -3.6 |
The primary objective of the study was to evaluate the safety and tolerability of ADS-5102 oral capsules, an extended release (ER) formulation of amantadine, administered at a dose of 340 mg once daily at bedtime for the treatment of levodopa-induced dyskinesia (LID) in subjects with Parkinson's disease (PD). (NCT02202551)
Timeframe: Up to 101 weeks
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AE | Study drug-related AE | SAEs | Permanent discontinuation due to AE | Permanent discontinuation due to drug-related AE | Mild AEs | Moderate AEs | Mild drug-related AE | Moderate drug-related AE | Severe drug-related AE | |
| Group 1a | 57 | 31 | 16 | 12 | 4 | 12 | 25 | 16 | 12 | 3 |
| Group 1P | 70 | 45 | 21 | 21 | 15 | 13 | 36 | 15 | 23 | 7 |
| Group 2 | 23 | 16 | 6 | 6 | 4 | 3 | 13 | 3 | 12 | 1 |
| Group 3 | 55 | 32 | 17 | 10 | 8 | 11 | 26 | 5 | 22 | 5 |
The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD. The UDysRS was measured at Baseline and Weeks 2, 4, 8, and 12. (NCT02274766)
Timeframe: Baseline to Week 12
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -6.3 |
| ADS-5102 (Amantadine HCl Extended Release) | -20.7 |
A PD home diary was used to score 5 different conditions in 30-minute intervals: ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia. The results were based on 2 consecutive 24-hour diaries taken prior to the day of randomization and prior to the Week 2, 4, 8, and 12 visits. (NCT02274766)
Timeframe: Baseline to Week 12
| Intervention | hours (Least Squares Mean) | ||
|---|---|---|---|
| Change in ON time without troublesome dyskinesia | Change in ON time with troublesome dyskinesia | Change in OFF time | |
| ADS-5102 (Amantadine HCl Extended Release) | 3.95 | -3.61 | -0.49 |
| Placebo | 2.05 | -2.47 | 0.61 |
Area under the curve for the root mean squared velocity in the anterior-posterior direction as measured by a forceplate. (NCT00794313)
Timeframe: Every 1/2 hour for 8 hour levodopa cycle
| Intervention | (meters/second)*hours (Mean) |
|---|---|
| Amantadine | 10.4 |
| Amantadine Plus Topiramate | 9.4 |
| Sugar Pill | 19.1 |
Area under the curve computed for whole body (total) mAIMS (Modified Abnormal Involuntary Movement Scale) scores at each time measurement. This is a commonly utilized scale that is completed by an observer who judges the severity of levodopa induced dyskinesia (LID) in 7 body parts (face, neck, trunk, both legs, and both arms). All body parts are rated separately on this 0 (none) to 4 (severe - markedly impairs activities) scale. Thus, the total score can range from 0 - 28 with 28 indicating the most severe LID. mAIMS ratings occur as the subject performs the cognitive task while standing on the force plate. mAIMS ratings are made every half hour during the levodopa (LD) dose cycle. (NCT00794313)
Timeframe: Measured every 1/2 hour for a levodopa dose cycle (starting 1 hour prior to infusion and ending 4 hours post 2-hour infusion)
| Intervention | Units on a Scale * Hours (Mean) |
|---|---|
| Amantadine | 4.0 |
| Amantadine Plus Topiramate | 5.3 |
| Sugar Pill | 8.5 |
26 reviews available for amantadine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Amantadine Revisited: A Contender for Initial Treatment in Parkinson's Disease?
Topics: Amantadine; Animals; Antiparkinson Agents; Confusion; Delayed-Action Preparations; Dopamine; Drug Th | 2021 |
Amantadine in the treatment of Parkinson's disease and other movement disorders.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2021 |
GOCOVRI
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase; Delayed-Action Preparations; Dyskine | 2022 |
Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Bias; Constipation; Del | 2019 |
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Development; Drug Repositioning; Dyskinesia, Drug-In | 2020 |
Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Ami | 2018 |
The role of extended-release amantadine for the treatment of dyskinesia in Parkinson's disease patients.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Drug Delivery Systems; Dyskinesia, Drug- | 2018 |
Amantadine Extended-Release (GOCOVRI
Topics: Amantadine; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, | 2018 |
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2019 |
Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Delayed-Action Preparations; Dyskinesia, Drug-In | 2019 |
Current treatment and future prospects of dopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dose-Response Relationship | 2015 |
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
Topics: Amantadine; Anti-Dyskinesia Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; P | 2016 |
[Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
Topics: Amantadine; Antiparkinson Agents; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Humans; Levodopa | 2017 |
Molecular mechanisms of l-DOPA-induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Genes, Immediate | 2011 |
N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis.
Topics: Amantadine; Databases, Factual; Disability Evaluation; Double-Blind Method; Dyskinesia, Drug-Induced | 2012 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glut | 2003 |
Other pharmacological treatments for motor complications and dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Dyskin | 2005 |
Update on antiparkinsonian agents.
Topics: Aged; Amantadine; Antiparkinson Agents; Blood-Brain Barrier; Bromocriptine; Dose-Response Relationsh | 1982 |
[Pharmacodynamics and pharmacokinetics of memantine].
Topics: Amantadine; Animals; Antidepressive Agents; Body Temperature; Catalepsy; Dopamine; Dyskinesia, Drug- | 1983 |
Adverse effects of antiparkinsonian drugs.
Topics: Amantadine; Amphetamines; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ergot Alkaloids; Humans; H | 1981 |
The management of Parkinson's disease.
Topics: Adult; Aged; Amantadine; Bromocriptine; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; H | 1982 |
Parkinson's disease: drug therapy.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Cholinergic Antagonists; Dopamine Agonists; Dyskinesi | 1997 |
[Toxic and adverse neurological effects of anti-parkinsonian drugs].
Topics: Amantadine; Antiparkinson Agents; Bromocriptine; Cholinergic Antagonists; Dopamine Agents; Dyskinesi | 1999 |
Medical treatment of later-stage motor problems of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; | 1999 |
Medical treatment of levodopa-induced dyskinesias.
Topics: Amantadine; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2000 |
In search of treatment for tardive dyskinesia: review of the literature.
Topics: Amantadine; Antipsychotic Agents; Diagnosis, Differential; Dyskinesia, Drug-Induced; Humans; Levodop | 1979 |
26 trials available for amantadine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies.
Topics: Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Levodopa; P | 2022 |
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.
Topics: Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Hu | 2020 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug | 2017 |
Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study.
Topics: Amantadine; Anticonvulsants; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Me | 2017 |
Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Doubl | 2017 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Capsules; Delayed-Action Preparati | 2018 |
Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Doubl | 2019 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2014 |
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Dose- | 2015 |
Aripiprazole in L-dopa-induced dyskinesias: a one-year open-label pilot study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychot | 2009 |
Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, D | 2010 |
Which dyskinesia scale best detects treatment response?
Topics: Aged; Amantadine; Analysis of Variance; Antiparkinson Agents; Dose-Response Relationship, Drug; Doub | 2013 |
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Topics: Adult; Aged; Amantadine; Chorea; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method | 2002 |
Amantadine in Huntington's disease: open-label video-blinded study.
Topics: Aged; Amantadine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Hunti | 2002 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Human | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Com | 2006 |
On the coexistence of parkinsonism and tardive dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; | 1974 |
No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Antipsychotic Agents; Biperiden; Cross-Over Studies; Double-Blind Method; Dyskine | 1995 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, | 1998 |
Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 1999 |
A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Confidence Interval | 1997 |
Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-In | 2000 |
Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agents; Double-Blind Method; Drug Therapy, Combinat | 2001 |
Amantadine for dyskinesia in patients affected by severe Parkinson's disease.
Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedu | 2001 |
Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Bromocriptine; Chronic | 1978 |
Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
Topics: Adult; Amantadine; Antipsychotic Agents; Benztropine; Chronic Disease; Dyskinesia, Drug-Induced; Fem | 1987 |
66 other studies available for amantadine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulat
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Allosteric Regulation; Animals; | 2014 |
Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Ret | 2022 |
Striatal Neuronal Ensembles Reveal Differential Actions of Amantadine and Clozapine to Ameliorate Mice L-DOPA-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Calcium; Clozapine; Corpus Striatum; Disease Models, Anim | 2022 |
The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitat | 2022 |
[Parkinson's Disease with Intolerable Painful Dyskinesia: Standard Treatment and Subsequent Tips].
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Pain; Parkinson Diseas | 2022 |
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Ind | 2023 |
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.
Topics: Amantadine; Animals; Dopamine; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyski | 2023 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; D | 2020 |
Distinct anti-dyskinetic effects of amantadine and group II metabotropic glutamate receptor agonist LY354740 in a rodent model: An electrophysiological perspective.
Topics: Amantadine; Animals; Antiparkinson Agents; Bridged Bicyclo Compounds; Corpus Striatum; Dyskinesia, D | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; D | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug- | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levo | 2020 |
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.
Topics: Aged; Amantadine; Double-Blind Method; Drug Delivery Systems; Dyskinesia, Drug-Induced; Female; Huma | 2017 |
Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Topics: Amantadine; Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Ma | 2018 |
Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Delayed-Action Preparations; Drug Compounding; Dyskinesia, Drug-In | 2017 |
Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior Rating Scale; Behavior, Animal; Disease Models, | 2018 |
Disabling tremor induced by long-term use of sodium valproate and lamotrigine: Case report.
Topics: Amantadine; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Dyskinesias; Humans; La | 2017 |
Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levod | 2019 |
TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.
Topics: Amantadine; Animals; Azabicyclo Compounds; Cyclopropanes; Dose-Response Relationship, Drug; Dyskines | 2013 |
Amantadine's role in the treatment of levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Antiviral Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Park | 2014 |
Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Topics: Amantadine; Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Respon | 2014 |
Predicting the development of levodopa-induced dyskinesias: a presynaptic mechanism?
Topics: Amantadine; Antiparasitic Agents; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Humans; Levodopa | 2014 |
Withdrawing amantadine in dyskinetic patients with Parkinson disease: The AMANDYSK trial.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Parkinson Disease | 2014 |
Author response.
Topics: Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Parkinson Disease | 2014 |
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease.
Topics: Amantadine; Animals; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, | 2016 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
Drug therapies for tardive dyskinesia: Part 1.
Topics: Amantadine; Antipsychotic Agents; Buspirone; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Move | 2011 |
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Data Interpretation, Statistical; Dyski | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dop | 2011 |
Retigabine, a K(V)7 (KCNQ) potassium channel opener, attenuates L-DOPA-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Amantadine; Aminopyridines; Animals; Anticonvulsants; Antiparkinson Agents; Behavior, Animal; Carbam | 2012 |
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.
Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Dis | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-In | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cycl | 2004 |
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amantadine; Animals; Anti-Dyskinesia Age | 2005 |
"Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease.
Topics: Aged; Amantadine; Benzothiazoles; Catechols; Dopamine Agents; Dose-Response Relationship, Drug; Drug | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Low-dose levodopa therapy in Japanese patients with Parkinson's disease: a retrospective study.
Topics: Aged; Amantadine; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Hallucinations; | 2005 |
Effects of N-methyl-D-aspartate receptor antagonism on neuroleptic-induced orofacial dyskinesias.
Topics: Allosteric Regulation; Amantadine; Animals; Antipsychotic Agents; Dextrorphan; Dose-Response Relatio | 2006 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Anticholinergics promote neuroleptic-induced tardive dyskinesia.
Topics: Amantadine; Animals; Antipsychotic Agents; Benztropine; Dextroamphetamine; Drug Synergism; Dyskinesi | 1980 |
Noncatecholaminergic treatments of tardive dyskinesia.
Topics: Amantadine; Anti-Anxiety Agents; Benzodiazepines; Cyproheptadine; D-Ala(2),MePhe(4),Met(0)-ol-enkeph | 1982 |
[Therapeutic measures in tardive dyskinesia].
Topics: Age Factors; Amantadine; Antipsychotic Agents; Baclofen; Benzodiazepines; Bromocriptine; Deanol; Dih | 1983 |
Amantadine in the management of extrapyramidal side effects.
Topics: Amantadine; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Dystonia; Humans | 1983 |
Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
Topics: Adult; Aged; Amantadine; Antipsychotic Agents; Dementia; Dose-Response Relationship, Drug; Drug Ther | 1982 |
The drug treatment of Parkinson's disease.
Topics: Amantadine; Bromocriptine; Cardiovascular Diseases; Chemical Phenomena; Chemistry; Drug Therapy, Com | 1984 |
Amantadine in Tourette syndrome.
Topics: Adolescent; Adult; Amantadine; Child; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; H | 1983 |
The role of various forms of treatment in the management of Parkinson's disease.
Topics: Amantadine; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergot | 1982 |
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics.
Topics: Adult; Amantadine; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Sched | 1995 |
[A case of multiple system atrophy presenting a regular involuntary movement of the neck muscles synchronous with respiration].
Topics: Amantadine; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Middle Aged; Muscular Atrophy; Neck Mu | 1993 |
Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Topics: Adult; Aged; Amantadine; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Ad | 1997 |
[Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; | 1997 |
Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dopamine Ag | 1998 |
New use for an old drug: amantadine benefits levodopa-induced dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administra | 1998 |
Drug treatments of levodopa-induced dyskinesias.
Topics: Amantadine; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid A | 1999 |
[Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; | 2000 |
[L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
Topics: Amantadine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease | 2001 |
Paradoxical response to dopamine agonists in tardive dyskinesia.
Topics: Adrenergic alpha-Agonists; Adult; Amantadine; Apomorphine; Benztropine; Clozapine; Deanol; Dextroamp | 1977 |
For mental patients, the 'cure' may be worse.
Topics: Amantadine; Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Risk; Schizophrenia | 1979 |
[Sustained levodopa efficacy in parkinsonism. Results of a four-year long-term follow-up study (author's transl)].
Topics: Activities of Daily Living; Aged; Amantadine; Carboxy-Lyases; Dose-Response Relationship, Drug; Drug | 1977 |
The combination of amantadine and neuroleptics plus time may cure tardive dyskinesia.
Topics: Adolescent; Adult; Amantadine; Antipsychotic Agents; Drug Administration Schedule; Drug Therapy, Com | 1989 |
Recent developments in the treatment of Parkinson's disease.
Topics: Aged; Aging; Amantadine; Diagnosis, Differential; Drug Administration Schedule; Dyskinesia, Drug-Ind | 1985 |
Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Benserazide; Carbidopa; Drug Ther | 1986 |